Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel
LON:AGY

Allergy Therapeutics 2/16/2026 Earnings Report

Allergy Therapeutics logo
GBX 9.98 0.00 (0.00%)
As of 05:13 AM Eastern
ProfileEarnings History

Allergy Therapeutics EPS Results

Actual EPS
-GBX 0.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Allergy Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Allergy Therapeutics Announcement Details

Quarter
Date
2/16/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Allergy Therapeutics Earnings Headlines

Allergy Therapeutics agrees new debt funding
February 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/allergy-therapeutics-agrees-debt-funding-082600699.html
GSK grabs RAPT for $2.2B in big bet on food allergy drugs
January 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/gsk-grabs-rapt-for-2-2b-in-big-bet-on-food-allergy-drugs/ar-AA1UFcE1
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 14 at 1:00 AM  |  Porter & Company (Ad)
GSK digs in on allergies with $2.2 billion Rapt Therapeutics buyout
January 20, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/gsk-digs-in-on-allergies-with-2-2-billion-rapt-therapeutics-buyout/ar-AA1UAuW3
Allergy Therapeutics reports 7% revenue growth in first half
January 19, 2026  |  in.investing.comhttps://in.investing.com/news/stock-market-news/allergy-therapeutics-reports-7-revenue-growth-in-first-half-93CH-5193152
Allergy Therapeutics plc (AGY.L) - Yahoo Finance
July 11, 2025  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/AGY.L/
See More Allergy Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allergy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allergy Therapeutics and other key companies, straight to your email.

About Allergy Therapeutics

Allergy Therapeutics (LON:AGY) is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

View Allergy Therapeutics Profile
Earnings Tools